Recursion Pharmaceuticals is trading at $4.16, down 4.70%, with no clear company-specific explanation identified for the October 12 decline.

  • A pre-market item reported shares up 5.50% at $4.60, but noted no clear catalyst.
  • That earlier move does not explain the current decline.
  • Supplied market context was mixed and modest; available evidence does not tie the decline to a specific company, sector, or macro event.